Victory Capital Management’s Compass Therapeutics CMPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.2K Buy
15,606
+800
+5% +$1.65K ﹤0.01% 2501
2026
Q2
$32.4K Buy
14,806
+1,077
+8% +$3.18K ﹤0.01% 2422
2026
Q1
$72.6K Sell
13,729
-582
-4% -$3.36K ﹤0.01% 2293
2025
Q4
$76.8K Buy
14,311
+1,659
+13% +$7.66K ﹤0.01% 2297
2025
Q3
$44.3K Buy
12,652
+2,164
+21% +$6.84K ﹤0.01% 2351
2025
Q2
$27.3K Buy
+10,488
New +$21.6K ﹤0.01% 2424
2025
Q1
– Sell
-10,536
Closed -$15.3K – 2487
2024
Q4
$15.3K Sell
10,536
-356
-3% -$591 ﹤0.01% 2458
2024
Q3
$20K Sell
10,892
-573
-5% -$714 ﹤0.01% 2443
2024
Q2
$11.5K Buy
11,465
+1,444
+14% +$2.11K ﹤0.01% 2461
2024
Q1
$19.8K Sell
10,021
-1,010
-9% -$1.74K ﹤0.01% 2445
2023
Q4
$17.2K Buy
+11,031
New +$19.1K ﹤0.01% 2514

Other funds holding CMPX

Victory Capital Management's CMPX Position: Q3 2026 in Review

Victory Capital Management increased its Compass Therapeutics (CMPX) stake by 5.4% in Q3 2026, buying an estimated $1.65K and bringing the position to 15,606 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2501.

Victory Capital Management first reported a position in CMPX in Q4 2023 and has held it in 11 quarters since. The position peaked at $76.8K in Q4 2025. 116 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • Victory Capital Management held 15,606 shares of Compass Therapeutics worth $16.2K as of Q3 2026.
  • Victory Capital Management bought 800 Compass Therapeutics shares in Q3 2026, an estimated $1.65K.
  • Compass Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q3 2026, its #2501 holding.
  • Victory Capital Management first reported a position in Compass Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Victory Capital Management's Compass Therapeutics position peaked at $76.8K in Q4 2025.
  • 116 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.